Literature DB >> 9724078

Comparative genomic hybridization studies in tumours from a patient with multiple endocrine neoplasia type 1.

S Kytölä1, M J Mäkinen, M Kähkönen, B T Teh, J Leisti, P Salmela.   

Abstract

OBJECTIVE: To identify genetic changes, other than the MEN1 gene, that might be involved in the tumorigenesis and progression of multiple endocrine neoplasia type 1 (MEN1)-related tumours.
METHODS: We used comparative genomic hybridization (CGH) and loss of heterozygosity (LOH) to study tumours from various sites in a patient with MEN1.
RESULTS: Gain of genetic material was not found. Frequent losses of genetic material were found in chromosomes 1, 4, 5, 6, 9, 11 and 18. Besides the chromosome 11 where the MEN1 gene is located, the other regions are known to harbour important tumour suppressor genes.
CONCLUSIONS: These results suggest the involvement of other cancer-related genes in the tumorigenesis and progression of MEN1 tumours that warrant further investigations.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9724078     DOI: 10.1530/eje.0.1390202

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  3 in total

1.  The Art and Applications of Fluorescence In Situ Hybridization in Endocrine Pathology.

Authors:  George Kontogeorgos
Journal:  Endocr Pathol       Date:  2000       Impact factor: 3.943

2.  Pituitary pathology in Carney complex patients.

Authors:  Sotirios G Stergiopoulos; Mones S Abu-Asab; Maria Tsokos; Constantine A Stratakis
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

3.  ARMC5 Alterations in Patients With Sporadic Neuroendocrine Tumors and Multiple Endocrine Neoplasia Type 1 (MEN1).

Authors:  Svetozar S Damjanovic; Jadranka A Antic; Valentina I Elezovic-Kovacevic; Dusko M Dundjerovic; Ivana T Milicevic; Bojana B Beleslin-Cokic; Bojana B Ilic; Gordana S Rodic; Annabel Berthon; Andrea Gutierrez Maria; Fabio R Faucz; Constantine A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2020-12-01       Impact factor: 5.958

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.